Evidence map›Paper›PMID 31227925›Full record

ReviewCurrent treatment options in neurology2019

Immune-Mediated Neuropathies.

Mithila Fadia, Sheetal Shroff, Ericka Simpson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mithila FadiaHouston Methodist Neurological Institute, 6560 Fannin Street, Ste 802, Houston, TX, 77030, USA.
Sheetal ShroffHouston Methodist Neurological Institute, 6560 Fannin Street, Ste 802, Houston, TX, 77030, USA.
Ericka SimpsonHouston Methodist Neurological Institute, 6560 Fannin Street, Ste 802, Houston, TX, 77030, USA. Esimpson@houstonmethodist.org.
Houston Methodist · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe purpose of this review article is to discuss the pathogenesis of acute and chronic immune-mediated neuropathies along with the recent advances in their treatment. RECENT

findingsSince the first description of Guillain-Barre syndrome (GBS) more than a century ago, there have been numerous forms of immune-mediated neuropathies described expanding the spectrum. Understanding the role of the immune system in the pathogenesis of immune-mediated neuropathies has been an advancement towards the diagnosis and treatment. It is postulated that immune-mediated neuropathies are a group of diseases resulting from autoimmunity towards multiple components of peripheral nervous system. These have a wide range of pathologic mechanisms, defined clinical presentations, electro-diagnostic and laboratory findings which help in diagnosis and management. Although immunosuppression is the common modality of treatment for these disorders, uncovering distinct pathogenic mechanisms can allow for targeted immunomodulation.

Indexed as

AIDPCancer-related neuropathyCIDPImmune neuropathy treatmentIVIgMMN

Identifiers

PMID31227925
OpenAlexW2950098165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.